During the recent session, Acadia Pharmaceuticals Inc (NASDAQ:ACAD)’s traded shares were 0.62 million, with the beta value of the company hitting 0.70. At the last check today, the stock’s price was $21.62, reflecting an intraday loss of -1.99% or -$0.44. The 52-week high for the ACAD share is $25.23, that puts it down -16.7 from that peak though still a striking 38.02% gain since the share price plummeted to a 52-week low of $13.40. The company’s market capitalization is $3.62B, and the average intraday trading volume over the past 10 days was 1.99 million shares, and the average trade volume was 2.16 million shares over the past three months.
Acadia Pharmaceuticals Inc (ACAD) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.85. ACAD has a Sell rating from 1 analyst(s) out of 16 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 14 recommend a Buy rating for it.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) trade information
Acadia Pharmaceuticals Inc (ACAD) registered a -1.99% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.99% in intraday trading to $21.62, hitting a weekly high. The stock’s 5-day price performance is 3.20%, and it has moved by -2.61% in 30 days. Based on these gigs, the overall price performance for the year is 17.82%. The short interest in Acadia Pharmaceuticals Inc (NASDAQ:ACAD) is 15.44 million shares and it means that shorts have 6.15 day(s) to cover.
The consensus price target of analysts on Wall Street is $24, which implies an increase of 9.92% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $32 respectively. As a result, ACAD is trading at a discount of -48.01% off the target high and -1.76% off the low.
While earnings are projected to return -62.78% in 2025, the next five years will return 4.69% per annum.
ACAD Dividends
Acadia Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD)’s Major holders
Acadia Pharmaceuticals Inc insiders own 0.57% of total outstanding shares while institutional holders control 105.53%, with the float percentage being 106.13%. BAKER BROS. ADVISORS LP is the largest shareholder of the company, while 428.0 institutions own stock in it. As of 2024-06-30, the company held over 42.88 million shares (or 25.9001% of all shares), a total value of $696.77 million in shares.
The next largest institutional holding, with 13.71 million shares, is of VANGUARD GROUP INC’s that is approximately 8.2827% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $222.82 million.
Also, the Mutual Funds coming in first place with the largest holdings of Acadia Pharmaceuticals Inc (ACAD) shares are iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on May 31, 2025 indicates that iShares Trust-iShares Core S&P Small-Cap ETF owns about 7.4 shares. This amounts to just over 4.42 percent of the company’s overall shares, with a $159.57 million market value. The same data shows that the other fund manager holds slightly less at 3.94, or about 2.35% of the stock, which is worth about $84.97 million.
